Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in the Phase III clinical study ...
Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.
Priority review and Project Orbis evaluation advance potential post-neoadjuvant use of trastuzumab deruxtecan for high-risk ...
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a cell line ...
Liège-based Bio‑Sourcing and Roanoke-based The Tiny Cargo Company inked a strategic collaboration to co‑develop orally delivered monoclonal antibody (mAb)-based therapies formulated using goat ...
Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...
PATINA supports adding palbociclib to anti-HER2 plus endocrine therapy in HR+/HER2+ disease, and HER2CLIMB-05 validates ...
FDA Priority Review was granted for trastuzumab deruxtecan in post-neoadjuvant HER2-positive early breast cancer with ...
ENHERTU Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer ...
Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced ...
In this video, Paolo Tarantino, MD, PhD, an advanced fellow at Dana-Farber Cancer Institute, discusses the pros and cons of trastuzumab deruxtecan in neoadjuvant and adjuvant settings.Tarantino said a ...
5don MSN
Combination treatment benefits patients with advanced breast cancer that has spread to the brain
Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results